Covid-19 roundup: New preprint sug­gests Omi­cron sub-vari­ant can evade Vir an­ti­body; BioN­Tech-backed non­prof­it un­der­mined WHO eq­ui­ty ef­forts — re­port

Af­ter Omi­cron be­gan spread­ing across the world, it quick­ly be­came clear that Vir-GSK’s an­ti­body sotro­vimab would be the on­ly FDA-ap­proved Covid-19 mon­o­clon­al an­ti­body treat­ment to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER